179 related articles for article (PubMed ID: 2989419)
21. Efficacy of a nucleic acid free herpetic subunit vaccine.
Cappel R; de Cuyper F; Rickaert F
Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864
[TBL] [Abstract][Full Text] [Related]
22. Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.
Weinberg A; Konrad M; Merigan TC
J Virol; 1987 Jul; 61(7):2120-7. PubMed ID: 3035213
[TBL] [Abstract][Full Text] [Related]
23. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment.
Wade JC; Day LM; Crowley JJ; Meyers JD
J Infect Dis; 1984 May; 149(5):750-6. PubMed ID: 6327849
[TBL] [Abstract][Full Text] [Related]
24. Antibody response to herpes simplex virus type 1 polypeptides and glycoproteins in primary and recurrent infection.
Mann DR; Hilty MD
Pediatr Res; 1982 Mar; 16(3):176-80. PubMed ID: 6278389
[TBL] [Abstract][Full Text] [Related]
25. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
26. The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.
Bernstein DI; Lovett MA; Bryson YJ
J Infect Dis; 1984 Jul; 150(1):7-13. PubMed ID: 6086772
[TBL] [Abstract][Full Text] [Related]
27. Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.
Ashley R; Wald A; Corey L
J Virol; 1994 Aug; 68(8):5284-6. PubMed ID: 8035526
[TBL] [Abstract][Full Text] [Related]
28. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences.
Kutinová L; Benda R; Kalos Z; Dbalý V; Votruba T; Kvícalová E; Petrovská P; Doutlík S; Kamínková J; Domorázková E
Vaccine; 1988 Jun; 6(3):223-8. PubMed ID: 2844031
[TBL] [Abstract][Full Text] [Related]
29. Confirmation of herpes simplex virus type 2 infections in herpes-like genital lesions by a simple complement-fixation test.
Arsenakis M; May JT
Br J Vener Dis; 1982 Feb; 58(1):48-51. PubMed ID: 6275941
[TBL] [Abstract][Full Text] [Related]
30. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy.
Bernstein DI; Harrison CJ; Jenski LJ; Myers MG; Stanberry LR
J Immunol; 1991 May; 146(10):3571-7. PubMed ID: 1851194
[TBL] [Abstract][Full Text] [Related]
31. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model.
Bos CA
Vaccine; 1988 Aug; 6(4):309-14. PubMed ID: 2847437
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
34. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs.
Harrison CJ; Miller RL; Bernstein DI
Antimicrob Agents Chemother; 1994 Sep; 38(9):2059-64. PubMed ID: 7811019
[TBL] [Abstract][Full Text] [Related]
35. Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine.
Thornton B; Baskerville A; Bailey NE; Melling JM; Hambleton P
Vaccine; 1984 Jun; 2(2):141-8. PubMed ID: 6099646
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
[TBL] [Abstract][Full Text] [Related]
37. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
38. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy.
Stanberry LR; Harrison CJ; Bernstein DI; Burke RL; Shukla R; Ott G; Myers MG
Antiviral Res; 1989; 11(4):203-14. PubMed ID: 2545166
[TBL] [Abstract][Full Text] [Related]
39. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial.
Skinner GR; Turyk ME; Benson CA; Wilbanks GD; Heseltine P; Galpin J; Kaufman R; Goldberg L; Hartley CE; Buchan A
Med Microbiol Immunol; 1997 Jun; 186(1):31-6. PubMed ID: 9255764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
